Why Comparing Wegovy and Ozempic Matters for Your Weight‑Loss Journey
If you searched for a wegovy vs ozempic comparison guide, start with the basics: both are GLP‑1 medications used by people pursuing weight loss. Focus on four decision factors:
- Efficacy
- Dosing
- Side effects
- Cost
Clinical trials show larger average weight loss with Wegovy than with lower‑dose Ozempic (roughly 15–18% vs about 8–14% of initial body weight over 68 weeks) (GoodRx GLP‑1 Comparison). Wegovy also showed a modest reduction in major cardiovascular events versus placebo in a large outcomes trial (FDA press release). Side effects are similar and mainly gastrointestinal; discontinuation rates vary by dose, population, and tolerability, so track symptoms with Pepio for informed clinician discussions.
Choosing between them comes down to how much weight loss you want, what dose schedule fits your life, and what side effects you can manage. Pepio helps you keep dose history, symptom notes, and weight progress together so you can compare experiences without relying on memory. People using Pepio find it easier to spot patterns after dose changes and to prepare clear notes for clinician visits. Learn more about Pepio’s approach to organizing GLP‑1 routines, and always follow your clinician, prescriber, or medication label for dosing and medical questions.
Pepio GLP‑1 Tracker: Your Foundation for Managing Any GLP‑1 Routine
A GLP-1 tracker is a single place to record dose, date, injection site, and symptoms. For people deciding between Wegovy and Ozempic, a tracker keeps practical details clear. This clarity matters because different GLP-1s can vary in dose schedule, side-effect timing, cost, and convenience (see an indirect comparison of outcomes and side effects for context) (Drugs.com Medical Answers).
Track the basics every time you inject.
- Medication name
- Dose
- Date
- Injection site
- Symptoms
- Weight
- BMI
Pepio’s iOS app adds push‑notification reminders; on the web, use the Next Dose Date Calculator and downloadable calendar reminders. Reminders help you keep a steady routine, and visible next-dose estimates make scheduling easier. When life gets busy, a reminder system stops you from guessing whether you already injected.
Symptom and weight charts help you spot trends to discuss with your clinician. Visual timelines make it easier to link nausea, appetite shifts, or plateaus to specific doses or dates. Exportable summaries and notes streamline appointments. Bring a clear, chronological record to follow-up visits so you can focus on questions, not reconstructing events.
Pepio helps keep these routine records in one place so your GLP-1 history is easy to review. Pepio is free, requires no sign‑up, and stores data locally in your browser; it also includes the Injection Site Rotator, FDA‑label titration schedules, compounded and universal dose calculators, and clinician‑ready PDF/CSV export. If you want a simple way to track injections, symptoms, and weight across different GLP‑1 options, try Pepio’s tools and calculators. Pepio is for organization and self-tracking only. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Wegovy: Efficacy, Dosing, Side Effects, and Cost
In the STEP 1 trial, adults with obesity who received Wegovy (semaglutide 2.4 mg) lost about 15% of body weight over 68 weeks, compared with 2.4% on placebo (STEP 1 trial) as reported by the FDA. The study population focused on adults with obesity, so trial results reflect that group rather than all potential users.
Wegovy uses a weekly injection with a stepwise titration. It typically starts at 0.25 mg once weekly and increases every four weeks until reaching 2.4 mg. Full escalation to the target dose generally takes about 16–20 weeks, as described in the FDA prescribing information.
Gastrointestinal side effects were the most common adverse events in trials. Pooled data show nausea occurred in about 44% of adults; diarrhea and vomiting each in roughly 20–30%; and constipation around 20–25% (varies by trial) according to the prescribing information. If your clinician prescribes Wegovy, keeping a simple symptom log can help you spot patterns and prepare concise notes for follow-up visits. Pepio helps you record symptoms, dates, and dose changes so you can review trends before appointments.
Cost is an important practical consideration. The average list price for Wegovy in the U.S. is roughly $1,350 per month, or about $16,200 per year. Actual out-of-pocket costs commonly range from about $300 to $1,500 per month depending on insurance and assistance programs (GoodRx price guide; GoodRx GLP-1 comparison). Users tracking supplies, refill timing, and cost can avoid surprises and plan conversations with their insurer or clinician.
With Pepio’s free, no-sign-up tools (and iOS push reminders), you can keep dose history, symptom notes, and optional refill/cost notes together for easier planning and clearer clinician conversations.
Pepio is for organization and self-tracking only. This section is informational and not medical advice. Always follow instructions from your clinician, prescriber, pharmacist, or medication label, and contact a healthcare professional if you have concerning or severe symptoms.
Ozempic: Efficacy, Dosing, Side Effects, and Cost
Ozempic (semaglutide) is indicated for type‑2 diabetes. In type‑2 diabetes trials, Ozempic 1 mg typically produces about 5–7% average weight loss, with 2 mg showing modestly greater reductions; results vary by dose and population and are generally less than the weight loss seen with 2.4 mg semaglutide used in Wegovy obesity trials (StatPearls). Many people on diabetes regimens stay at lower maintenance doses, while obesity protocols may titrate to higher weekly doses. Using Ozempic for weight‑loss alone is often off‑label; follow your clinician’s instructions. Use Pepio to track doses, shot dates, and weight progress so you have a clear record between visits.
The standard titration per the FDA label begins at 0.25 mg once weekly, increases to 0.5 mg after four weeks, then to 1 mg after another four weeks. Some obesity-focused protocols continue titration up to 2 mg under clinical supervision (FDA Ozempic Prescribing Information). These steps help the body adapt, but they do not replace your clinician’s instructions.
Gastrointestinal side effects are the most common adverse events. Nausea, vomiting, and diarrhea occur frequently, with pooled trial data showing nausea in about 20% of participants on Ozempic—modestly lower than rates reported at higher semaglutide doses for obesity (StatPearls). If you notice persistent or severe symptoms, contact a healthcare professional promptly.
Cost and coverage vary by location and indication. Retail prices for a 1 mg supply can be near $900 per month in the United States, though actual costs depend on pharmacy pricing and insurance benefits. Insurers commonly cover Ozempic for diabetes, but coverage for weight‑loss use is variable and often requires prior authorization (GoodRx GLP-1 Comparison; FDA Ozempic Prescribing Information).
Pepio helps you keep a clear record of your Ozempic doses, shot dates, symptoms, and weight progress so you can track trends between visits. Users of Pepio report more confidence recalling dose history and symptom timing during follow-ups. Pepio’s practical tracking approach supports organization, not medical decisions.
Pepio is for organization and self-tracking only. Pepio does not provide medical advice, dosing recommendations, or clinical guidance. Always follow instructions from your clinician, prescriber, pharmacist, or medication label. Learn more about Pepio’s approach to tracking GLP-1 routines and keeping your dose history, symptoms, and progress organized.
Side‑by‑Side Comparison: Wegovy vs Ozempic vs Pepio Tracker
Wegovy and Ozempic share a class and a weekly dosing rhythm, but they differ in dose, average weight loss, side‑effect rates, and cost. Clinical summaries show Wegovy produced roughly 15–18% average weight loss over 68 weeks versus about 12% for Ozempic in comparable cohorts (NJ Bariatric Center). Both are given once weekly, with Wegovy reaching a 2.4 mg maximum and Ozempic reaching 2 mg (GoodRx GLP‑1 Comparison). Gastrointestinal effects are common, slightly more so with Wegovy in trial data (JAMA Internal Medicine). Retail prices also differ, with Wegovy typically costing more per month than Ozempic (GoodRx price listings for Wegovy and Ozempic).
- Efficacy
Wegovy has shown about 15–18% average weight loss at 68 weeks versus about 12% for Ozempic in trial summaries (NJ Bariatric Center).
- Dosing schedule
Both drugs are administered once weekly; Wegovy’s max dose is 2.4 mg and Ozempic’s is 2 mg (GoodRx GLP‑1 Comparison).
- Common side effects
Gastrointestinal events (nausea, vomiting, diarrhea) are dose‑dependent and tend to be more common with higher‑dose semaglutide formulations used for obesity (Wegovy) than with lower‑dose Ozempic; trial reports and label information show GI rates vary by dose and individual tolerance (JAMA Internal Medicine).
- Average monthly cost
Typical out‑of‑pocket retail prices show Wegovy costing around $1,350 per month and Ozempic about $900–$950 per month before discounts; actual costs vary widely with insurance, coupons, and pharmacy (GoodRx price listings for Wegovy and Ozempic).
- How Pepio adds tracking value
Tracking can support adherence and recall. Pepio gives you push notifications (iOS), in‑browser logging, symptom and weight trend charts, and clinician‑ready PDF export so dose history, injection sites, and symptoms live in one place. Pepio is for organization and self‑tracking only and does not provide medical advice or dosing recommendations.
Choosing between Wegovy and Ozempic depends on goals, costs, and tolerance. For practical routine management, learn more about Pepio’s approach to tracking GLP‑1 routines so your dose history, symptoms, and progress stay organized before your next clinician conversation. Whichever medication you and your clinician choose, use Pepio—the free, privacy‑first GLP‑1 tracker—to log doses, injection sites, symptoms, and weight. Download the Pepio iOS app for push reminders and clinician‑ready PDF exports. Pepio keeps dose history, injection sites, symptoms, and weight progress in one private, exportable place.
Pepio is for organization and self‑tracking only. Pepio does not provide medical advice or dosing recommendations. Always follow instructions from your clinician, prescriber, pharmacist, or medication label.
Summing up the trade-offs, Wegovy and Ozempic differ mainly on labeled use, typical weight results, cardiovascular data, side‑effect profiles, and cost. Clinical comparisons show higher average weight loss with higher‑dose semaglutide formulations in some studies (JAMA Internal Medicine, Drugs.com). Wegovy carries a cardiovascular benefit noted by the FDA for people with obesity and heart risk factors (FDA press release). Cost and insurance coverage also vary widely between formulations and pharmacies (GoodRx, GoodRx).
Who might lean toward one option over the other?
-
People focused on labeled weight‑management benefits and cardiovascular data may favor Wegovy, after clinician review (Wegovy label).
-
Those managing type‑2 diabetes who also want weight benefits may consider Ozempic, given its diabetes indication and safety profile (Ozempic label, StatPearls).
-
Cost, access, and side‑effect tolerance often drive practical choice more than trial averages (GoodRx GLP‑1 comparison, BuzzRx review).
Keep a clear record of your routine, dose changes, symptoms, injection sites, and weight progress. Pepio helps you log those details so your notes are ready for clinical conversations. Users using Pepio experience simpler dose history and symptom tracking, which makes follow‑ups easier. Learn more about Pepio’s approach to tracking GLP‑1 routines and how it can keep your routine organized.
Pepio is for organization and self‑tracking only. Pepio does not provide medical advice, dosing recommendations, or treatment decisions. Ask your clinician before starting, stopping, or changing medication, or if you have concerning or severe symptoms.